Flow Cytometry
流式细胞仪
基本信息
- 批准号:7930103
- 负责人:
- 金额:$ 18.83万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-07-15 至 2015-06-30
- 项目状态:已结题
- 来源:
- 关键词:AIDS VaccinesAIDS therapyAcademic Medical CentersAcquired Immunodeficiency SyndromeAnimalsArtsBasic ScienceCellsClinical ResearchColorCore FacilityDevelopmentFlow CytometryFluorescence-Activated Cell SortingHIVHIV-1HousingHumanImmunologic MonitoringInformaticsInvestigationLaboratoriesLifeLinkProcessResearchResearch PersonnelScientistSorting - Cell MovementSpecimenTechnologyTranslational Researchbaseglobal healthmembernovelpathogenresearch facilitytool
项目摘要
CoreC
The proposed Duke CFAR Flow Cytometry Core Facility will a) provide state-of-the-art, multi-color, BSL-3 fluorescence activated cell sorting support for basic research or translational investigations conducted by Duke CFAR members, including sorting HIV-1 infected cells, b) provide state-of-the-art, multi-color, BSL-2* flow cytometric analytical support for basic, translational, and clinical research investigations conducted by Duke CFAR members, and c) enhance the scientific approach used by Duke CFAR Investigators by educating the Core User base in more effective ways of utilizing the state-of-the-art tools offered by the Duke CFAR Flow Cytometry Core Facility, as well as to provide programmatic advancement for Managers and Operators of the CFAR Flow Cytometry Core Facility. The BSL-3 Sorting Component Laboratory will house the only flow cytometer at Duke University Medical Center capable of sorting live, unfixed human or animal derived cells, infected with HIV-1 or equivalent pathogens, and will prove an invaluable asset to the overall scope of the proposed Duke CFAR Flow Cytometry Core Facility. The Duke CFAR Flow Cytometry Core will be the only flow cytometry facility at Duke capable of providing polychromatic and flow informatic support for HIV and HIV-related translational research at Duke. The proposed Duke CFAR Flow Cytometry Core Facility will be comprised of two Component Laboratories, both housed in biocontainment laboratories within the SORF & Global Health Buildings, respectively. The Component Laboratories will be closely linked physically, administratively, and scientifically, in order to form a highly interactive and unified Duke CFAR Flow Cytometry Core Facility. The BSL-2* Analytical Component Laboratory will provide a broad range of polychromatic flow cytometry applications to CFAR investigators and, together with the BSL-3 Sorting Component Laboratory, comprise the only flow cytometry research facility on campus that routinely processes, sorts, and analyzes HIV-1 infected specimens.
Corec
拟议的杜克CFAR流式细胞术核心设施将a)为杜克CFAR成员进行的基础研究或转化研究提供最先进的多色BSL-3荧光激活细胞分选支持,包括分选HIV-1感染细胞,B)为基础、转化、和杜克CFAR成员进行的临床研究调查,以及c)通过教育核心用户群更有效地利用杜克CFAR流式细胞术核心机构提供的最先进工具,增强杜克CFAR研究者使用的科学方法,以及为CFAR流式细胞术核心设施的管理者和操作者提供程序化的进步。BSL-3分选组件实验室将容纳杜克大学医学中心唯一的流式细胞仪,该流式细胞仪能够分选感染HIV-1或同等病原体的活的、未固定的人或动物源细胞,并将证明是拟议的杜克CFAR流式细胞仪核心设施整体范围的宝贵资产。杜克CFAR流式细胞术核心将是杜克唯一能够为杜克的HIV和HIV相关转化研究提供多色和流式信息支持的流式细胞术设施。拟议的杜克CFAR流式细胞术核心设施将由两个组件实验室组成,分别位于SORF和全球卫生大楼内的生物防护实验室内。组件实验室将在物理上、行政上和科学上紧密联系,以形成高度互动和统一的杜克CFAR流式细胞术核心设施。BSL-2* 分析成分实验室将为CFAR研究人员提供广泛的多色流式细胞术应用,并与BSL-3分选成分实验室一起,组成校园内唯一的流式细胞术研究设施,定期处理,分选和分析HIV-1感染标本。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kent J. Weinhold其他文献
Preparation and characterization of an intravenous solution of IgG from human immunodeficiency virus-seropositive donors.
来自人类免疫缺陷病毒血清阳性供体的 IgG 静脉注射溶液的制备和表征。
- DOI:
10.1182/blood.v77.5.1111.bloodjournal7751111 - 发表时间:
1991 - 期刊:
- 影响因子:20.3
- 作者:
Larry M. Cummins;Kent J. Weinhold;Thomas J. Matthews;A. J. Langlois;C. F. Perno;RICHARD M. Condie;Jean - 通讯作者:
Jean
Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein.
HIV 包膜糖蛋白中和单克隆抗体的特征。
- DOI:
- 发表时间:
1988 - 期刊:
- 影响因子:1.5
- 作者:
Michael A. Skinner;Robert Ting;A. J. Langlois;Kent J. Weinhold;H. K. Lyerly;K. Javaherian;Thomas J. Matthews - 通讯作者:
Thomas J. Matthews
3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase
3-叠氮基-3-脱氧胸苷三磷酸作为纯化人免疫缺陷病毒逆转录酶的抑制剂和底物
- DOI:
10.1128/aac.31.12.1972 - 发表时间:
1987 - 期刊:
- 影响因子:4.9
- 作者:
M. H. S. Clair;Cynthia A. Richards;Thomas Spector;Kent J. Weinhold;Wayne H. Miller;A. J. Langlois;Phillip A. Furman - 通讯作者:
Phillip A. Furman
Measurement of direct and indirect forms of anti-HIV-1 ADCC: implications for other retroviral disease.
抗 HIV-1 ADCC 的直接和间接形式的测量:对其他逆转录病毒疾病的影响。
- DOI:
- 发表时间:
1990 - 期刊:
- 影响因子:0
- 作者:
Kent J. Weinhold;Douglas S. Tyler;H. K. Lyerly - 通讯作者:
H. K. Lyerly
Coupling Hematoma Evacuation with Immune Profiling for Analysis of Neuroinflammation After Primary Intracerebral Hemorrhage: A Pilot Study
- DOI:
10.1016/j.wneu.2022.02.062 - 发表时间:
2022-05-01 - 期刊:
- 影响因子:
- 作者:
Jay B. Lusk;Quintin J. Quinones;Janet S. Staats;Kent J. Weinhold;Peter M. Grossi;Shahid M. Nimjee;Daniel T. Laskowitz;Michael L. James - 通讯作者:
Michael L. James
Kent J. Weinhold的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kent J. Weinhold', 18)}}的其他基金
Biorepository, Pathology, and Immune Monitoring Core
生物样本库、病理学和免疫监测核心
- 批准号:
10248315 - 财政年份:2014
- 资助金额:
$ 18.83万 - 项目类别:
Biorepository, Pathology, and Immune Monitoring Core
生物样本库、病理学和免疫监测核心
- 批准号:
10705239 - 财政年份:2014
- 资助金额:
$ 18.83万 - 项目类别:
相似海外基金
Basic and applied study on AIDS-therapy using hybrid liposomes
混合脂质体治疗艾滋病的基础与应用研究
- 批准号:
24656509 - 财政年份:2012
- 资助金额:
$ 18.83万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
SIV MODEL FOR MULTI DRUG RESISTANCE TO AIDS THERAPY
艾滋病治疗多重耐药性的 SIV 模型
- 批准号:
6940442 - 财政年份:2003
- 资助金额:
$ 18.83万 - 项目类别:
RT-SHIV MODEL FOR RESISTANCE TO AIDS THERAPY
艾滋病治疗抵抗力的 RT-SHIV 模型
- 批准号:
6940441 - 财政年份:2003
- 资助金额:
$ 18.83万 - 项目类别:
Mitochondrial Toxicity of Antiviral Nucleosides in AIDS Therapy
艾滋病治疗中抗病毒核苷的线粒体毒性
- 批准号:
7421121 - 财政年份:2002
- 资助金额:
$ 18.83万 - 项目类别:
Targeted Manipulation of Stem Cells for AIDS Therapy
干细胞的靶向操作用于艾滋病治疗
- 批准号:
7479315 - 财政年份:2001
- 资助金额:
$ 18.83万 - 项目类别:
TARGETED MANIPULATION OF STEM CELLS FOR AIDS THERAPY
干细胞的靶向操作用于艾滋病治疗
- 批准号:
6312501 - 财政年份:2001
- 资助金额:
$ 18.83万 - 项目类别:
TARGETED MANIPULATION OF STEM CELLS FOR AIDS THERAPY
干细胞的靶向操作用于艾滋病治疗
- 批准号:
6499098 - 财政年份:2001
- 资助金额:
$ 18.83万 - 项目类别:
Targeted Manipulation of Stem Cells for AIDS Therapy
干细胞的靶向操作用于艾滋病治疗
- 批准号:
7666728 - 财政年份:2001
- 资助金额:
$ 18.83万 - 项目类别:
TARGETED MANIPULATION OF STEM CELLS FOR AIDS THERAPY
干细胞的靶向操作用于艾滋病治疗
- 批准号:
6708893 - 财政年份:2001
- 资助金额:
$ 18.83万 - 项目类别:
TARGETED MANIPULATION OF STEM CELLS FOR AIDS THERAPY
干细胞的靶向操作用于艾滋病治疗
- 批准号:
6849724 - 财政年份:2001
- 资助金额:
$ 18.83万 - 项目类别:














{{item.name}}会员




